Evidence map›Paper›PMID 41805109›Full record

ArticleDrug development research2026

Structure-Guided Optimization and Biological Validation of 1,3,4-Thiadiazole-Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions.

Ahmet Bugra Aksel, Fikriye Ozgencil, Filiz Bakar-Ates, Habibe Beyza Gunindi, Alberto Massarotti, Erva Ozkan, Selen Gozde Kaya, Mahmut Gozelle, Yesim Ozkan, Gokcen Eren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmet Bugra AkselDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-5090-6474
Fikriye OzgencilDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-3664-4150
Filiz Bakar-AtesDepartment of Biochemistry, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-2809-8946
Habibe Beyza GunindiDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0009-0004-5885-812X
Alberto MassarottiDipartimento di Scienze del Farmaco, Università degli Studi del Piemonte Orientale, Novara, Italy.ORCID https://orcid.org/0000-0001-9306-8845
Erva OzkanDepartment of Biochemistry, Faculty of Pharmacy, Ankara Medipol University, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-9461-2339
Selen Gozde KayaDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-3749-3008
Mahmut GozelleDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-0234-6577
Yesim OzkanDepartment of Biochemistry, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0002-1669-4962
Gokcen ErenDepartment of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID https://orcid.org/0000-0002-3420-607X

Funding

Gazi University Scientific Research Projects Coordination Unit (Ankara, Türkiye) TOA-2021-7165
6 · The paper itself

Abstract

SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC

Indexed as

Antineoplastic AgentsHistone Deacetylase InhibitorsSirtuin 2ThiadiazolesBinding SitesCell ProliferationDrug DesignHumansMCF-7 CellsMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipTubulin1,3,4-thiadiazoleAntineoplastic AgentsHistone Deacetylase InhibitorsSIRT2 protein, humanSirtuin 2ThiadiazolesTubulinMCF‐7sirtuinthiadiazoleα‐tubulin

Identifiers

PMID41805109
PMCPMC12973487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.